Amedisys Resultados de beneficios anteriores

Pasado controles de criterios 3/6

Los beneficios de Amedisys han disminuido a una tasa media anual de -22%, mientras que en la industria Healthcare los beneficios crecieron en un 5.4% anualmente. Los ingresos han ido creciendo a una tasa media de 3.8% al año. La rentabilidad financiera de Amedisys es de 7.8%, y sus márgenes netos son de 4%.

Información clave

-22.0%

Tasa de crecimiento de los beneficios

-22.2%

Tasa de crecimiento del BPA

Crecimiento de la industria Healthcare	8.5%
Tasa de crecimiento de los ingresos	3.8%
Rentabilidad financiera	7.8%
Margen neto	4.0%
Última actualización de beneficios	30 Jun 2024

Actualizaciones de resultados anteriores recientes

Recent updates

An Intrinsic Calculation For Amedisys, Inc. (NASDAQ:AMED) Suggests It's 38% Undervalued

Sep 04

Amedisys: ROIC, Tangible Book Value Each Softening

Aug 24

Slowing Rates Of Return At Amedisys (NASDAQ:AMED) Leave Little Room For Excitement

Aug 04

Amedisys profit beats by $0.24, revenue misses by $25.23M, 2022 guidance below estimates

Jul 27

We Think Amedisys (NASDAQ:AMED) Can Stay On Top Of Its Debt

Jul 20

At US$115, Is It Time To Put Amedisys, Inc. (NASDAQ:AMED) On Your Watch List?

Jun 04

Returns On Capital At Amedisys (NASDAQ:AMED) Have Stalled

May 05

Is Amedisys, Inc. (NASDAQ:AMED) Trading At A 40% Discount?

Apr 20

Does Amedisys (NASDAQ:AMED) Deserve A Spot On Your Watchlist?

Apr 06

Is Amedisys (NASDAQ:AMED) A Risky Investment?

Feb 20

Amedisys (NASDAQ:AMED) Shareholders Will Want The ROCE Trajectory To Continue

Jan 19

Should You Be Adding Amedisys (NASDAQ:AMED) To Your Watchlist Today?

Dec 03

These 4 Measures Indicate That Amedisys (NASDAQ:AMED) Is Using Debt Safely

Nov 18

Amedisys (NASDAQ:AMED) Could Easily Take On More Debt

Aug 18

Calculating The Fair Value Of Amedisys, Inc. (NASDAQ:AMED)

Jul 23

Amedisys: Strategic Contessa Acquisition Underpins The Home Healthcare Growth Opportunity

Jul 18

Under The Bonnet, Amedisys' (NASDAQ:AMED) Returns Look Impressive

Jun 28

It Looks Like Shareholders Would Probably Approve Amedisys, Inc.'s (NASDAQ:AMED) CEO Compensation Package

Jun 02

Should You Be Adding Amedisys (NASDAQ:AMED) To Your Watchlist Today?

May 24

Desglose de ingresos y gastos

Cómo gana y gasta dinero Amedisys. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqGS:AMED Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A
30 Jun 24	2,290	92	782
31 Mar 24	2,251	-21	780
31 Dec 23	2,236	-10	780
30 Sep 23	2,228	3	774
30 Jun 23	2,229	2	769
31 Mar 23	2,234	112	763
31 Dec 22	2,223	119	754
30 Sep 22	2,220	121	745
30 Jun 22	2,216	140	736
31 Mar 22	2,222	191	723
31 Dec 21	2,214	209	711
30 Sep 21	2,206	220	1,033
30 Jun 21	2,196	247	911
31 Mar 21	2,117	202	785
31 Dec 20	2,072	184	668
30 Sep 20	2,021	166	216
30 Jun 20	1,972	128	214
31 Mar 20	1,980	127	219
31 Dec 19	1,956	127	608
30 Sep 19	1,889	127	207
30 Jun 19	1,812	124	197
31 Mar 19	1,731	123	189
31 Dec 18	1,663	119	185
30 Sep 18	1,626	88	181
30 Jun 18	1,583	71	178
31 Mar 18	1,546	42	178
31 Dec 17	1,511	30	177
30 Sep 17	1,474	43	181
30 Jun 17	1,456	40	187
31 Mar 17	1,438	46	190
31 Dec 16	1,419	37	196
30 Sep 16	1,391	41	198
30 Jun 16	1,358	38	193
31 Mar 16	1,313	38	188
31 Dec 15	1,266	-3	173
30 Sep 15	1,230	-7	158
30 Jun 15	1,204	-7	149
31 Mar 15	1,193	-10	142
31 Dec 14	1,188	13	147
30 Sep 14	1,191	-4	153
30 Jun 14	1,192	-103	161
31 Mar 14	1,203	-109	167
31 Dec 13	1,233	-93	170

Ingresos de calidad: AMED tiene una única gran pérdida de $49.1M que afecta a sus resultados financieros de los últimos 12 meses de 30th June, 2024.

Margen de beneficios creciente: Los actuales márgenes de beneficio (4%) de AMED son superiores a los del año pasado (0.1%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: Los beneficios de AMED han disminuido en un 22% al año en los últimos 5 años.

Acelerando crecimiento: El crecimiento de los beneficios de AMED en el último año (3847.8%) supera su media de 5 años (-22% al año).

Beneficios vs. Industria: El crecimiento de los beneficios de AMED en el último año (3847.8%) superó al de la industria Healthcare 11.4%.

Amedisys Resultados de beneficios anteriores

Pasado controles de criterios 3/6

Información clave

Actualizaciones de resultados anteriores recientes

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

First quarter 2024 earnings: EPS misses analyst expectations

Full year 2023 earnings: EPS misses analyst expectations

Third quarter 2023 earnings: EPS misses analyst expectations

Full year 2022 earnings: EPS exceeds analyst expectations

Amedisys, Inc. to Report Q4, 2022 Results on Feb 15, 2023

Recent updates

Final Push For Amedisys As UnitedHealth Awaits Regulatory Clearance

Michael P. North Leaves Amedisys, Inc. as Chief Information Officer and Compensation Committee of the Board of Directors, Effective August 31, 2024

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

First quarter 2024 earnings: EPS misses analyst expectations

Full year 2023 earnings: EPS misses analyst expectations

Insufficient new directors

President notifies of intention to sell stock

Consensus EPS estimates fall by 54%

Third quarter 2023 earnings: EPS misses analyst expectations

Option Care Health, Inc. (NasdaqGS:OPCH) cancelled the acquisition of Amedisys, Inc. (NasdaqGS:AMED).

Investor sentiment improves as stock rises 19%

Option Care Health, Inc. (NasdaqGS:OPCH) entered into an agreement and plan of merger to acquire Amedisys, Inc. (NasdaqGS:AMED) for $3.2 billion.

Price target decreased by 8.5% to US$98.85

Option Care Health, Inc. (NasdaqGS:OPCH) entered into an agreement and plan of merger to acquire Amedisys, Inc. (NasdaqGS:AMED) for $3.2 billion.

Is Amedisys, Inc. (NASDAQ:AMED) Trading At A 41% Discount?

Does Amedisys (NASDAQ:AMED) Have A Healthy Balance Sheet?

Full year 2022 earnings: EPS exceeds analyst expectations

Amedisys, Inc. (NasdaqGS:AMED) announces an Equity Buyback for $100 million worth of its shares.

Amedisys (NASDAQ:AMED) Will Be Hoping To Turn Its Returns On Capital Around

Chairman & CEO exercised options and sold US$221k worth of stock

Amedisys, Inc. to Report Q4, 2022 Results on Feb 15, 2023

At US$83.54, Is It Time To Put Amedisys, Inc. (NASDAQ:AMED) On Your Watch List?

A Look At The Fair Value Of Amedisys, Inc. (NASDAQ:AMED)

Insufficient new directors

Amedisys, Inc. Names Scott Ginn as Acting Chief Operating Officer

Amedisys, Inc. Announces CEO Changes

High number of new directors

Capital Allocation Trends At Amedisys (NASDAQ:AMED) Aren't Ideal

Consensus EPS estimates fall by 16%

Price target decreased to US$126

Amedisys, Inc. Provides Earnings Guidance for the Year 2022

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Amedisys, Inc. to Report Q3, 2022 Results on Oct 26, 2022

Amedisys, Inc. Announces Resignation of David L. Kemmerly as Chief Legal and Government Affairs Officer

Is Now The Time To Look At Buying Amedisys, Inc. (NASDAQ:AMED)?

An Intrinsic Calculation For Amedisys, Inc. (NASDAQ:AMED) Suggests It's 38% Undervalued

Amedisys: ROIC, Tangible Book Value Each Softening

Consensus EPS estimates fall by 11%

Slowing Rates Of Return At Amedisys (NASDAQ:AMED) Leave Little Room For Excitement

Price target decreased to US$145

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Amedisys profit beats by $0.24, revenue misses by $25.23M, 2022 guidance below estimates

We Think Amedisys (NASDAQ:AMED) Can Stay On Top Of Its Debt

Price target decreased to US$160

Amedisys, Inc. to Report Q2, 2022 Results on Jul 27, 2022

Amedisys, Inc.(NasdaqGS:AMED) dropped from Russell 1000 Growth-Defensive Index

At US$115, Is It Time To Put Amedisys, Inc. (NASDAQ:AMED) On Your Watch List?

Price target decreased to US$174

Returns On Capital At Amedisys (NASDAQ:AMED) Have Stalled

First quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new directors

Amedisys, Inc. Announces Promotion of Nick Muscato as Chief Strategy Officer

Is Amedisys, Inc. (NASDAQ:AMED) Trading At A 40% Discount?

Amedisys, Inc. to Report Q1, 2022 Results on Apr 27, 2022

Does Amedisys (NASDAQ:AMED) Deserve A Spot On Your Watchlist?

Amedisys, Inc. (NasdaqGS:AMED) completed the acquisition of Assets of AssistedCare Home Health, Inc. and RH Homecare Services, LLC.

Amedisys, Inc. Announces Resignation of Richard A. Lechleiter from the Board of Directors

Investor sentiment improved over the past week

Price target decreased to US$184

Chairman & CEO exercised options and sold US$2.8m worth of stock

Full year 2021 earnings: EPS misses analyst expectations

Amedisys, Inc. (NasdaqGS:AMED) signed a definitive agreement to acquire Assets of AssistedCare Home Health, Inc.

Is Amedisys (NASDAQ:AMED) A Risky Investment?

Amedisys, Inc. (NasdaqGS : AMED) agreed to acquire Evolution Health, LLC from Emergency Medical Services LP Corporation.

Amedisys, Inc. to Report Q4, 2021 Results on Feb 23, 2022

Amedisys (NASDAQ:AMED) Shareholders Will Want The ROCE Trajectory To Continue

High number of new directors

Investor sentiment improved over the past week

Lead Independent Director recently bought US$141k worth of stock